{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:41:56Z","timestamp":1760784116549},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jgo.2016.03.001","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T21:30:57Z","timestamp":1460842257000},"page":"169-175","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany"],"prefix":"10.1016","volume":"7","author":[{"given":"Louis","family":"Jacob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2016.03.001_bb0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-015-3530-0","article-title":"Impact of disease management programs on women with breast cancer in Germany","volume":"153","author":"Jacob","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2016.03.001_bb0010","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2217\/fon.13.140","article-title":"Breast cancer in the elderly: which lessons have we learned?","volume":"9","author":"Turner","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2009.02.003","article-title":"Hormone therapy in elderly breast cancer patients with comorbidities","volume":"73","author":"Crivellari","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2016.03.001_bb0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.6004\/jnccn.2009.0012","article-title":"Breast cancer. Clinical practice guidelines in oncology","volume":"7","author":"Carlson","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jgo.2016.03.001_bb0030","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2016.03.001_bb0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2016.03.001_bb0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2016.03.001_bb0045","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/cncr.23193","article-title":"Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer","volume":"112","author":"Buzdar","year":"2008","journal-title":"Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.jgo.2016.03.001_bb0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0960-9776(09)70002-5","article-title":"Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer","volume":"18","author":"Chlebowski","year":"2009","journal-title":"Breast"},{"key":"10.1016\/j.jgo.2016.03.001_bb0055","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Dowsett","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2016.03.001_bb0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jgo.2016.03.001_bb0065","first-page":"42","article-title":"Persistence with drug therapy: a practical approach using administrative claims data","volume":"10","author":"Dezii","year":"2001","journal-title":"Manag Care"},{"key":"10.1016\/j.jgo.2016.03.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.51.7367","article-title":"Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901","author":"Sheppard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2006.10.1022","article-title":"Predictors of tamoxifen discontinuation among older women with estrogen receptor\u2013positive breast cancer","volume":"26","author":"Owusu","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0080","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2014.59.3673","article-title":"Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer","volume":"33","author":"He","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0085","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jama.2012.84","article-title":"Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer","volume":"307","author":"van de Water","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jgo.2016.03.001_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-013-2417-1","article-title":"Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis","volume":"138","author":"Hadji","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2016.03.001_bb0095","doi-asserted-by":"crossref","DOI":"10.5600\/mmrr.001.04.a04","article-title":"Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D","volume":"1","author":"Riley","year":"2011","journal-title":"Medicare Medicaid Res Rev"},{"key":"10.1016\/j.jgo.2016.03.001_bb0100","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/jnci\/93.21.1615","article-title":"Tamoxifen and depression: more evidence from the national surgical adjuvant breast and bowel project\u2019s breast cancer prevention (P-1) randomized study","volume":"93","author":"Day","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2016.03.001_bb0105","first-page":"89","article-title":"Osteoporosis and aromatase inhibitors: experience and future prospects","volume":"9","author":"Bosco","year":"2012","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.jgo.2016.03.001_bb0110","article-title":"Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture","author":"Jacob","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jgo.2016.03.001_bb0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CPP47617","article-title":"Validity and representativeness of the \u201cDisease Analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies","volume":"47","author":"Becher","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jgo.2016.03.001_bb0120","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2008.19.2419","article-title":"Adjuvant hormonal therapy use among insured, low-income women with breast cancer","volume":"27","author":"Kimmick","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2016.03.001_bb0130","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10549-011-1703-z","article-title":"Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer","volume":"130","author":"Nekhlyudov","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2016.03.001_bb0135","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2010.33.3179","article-title":"Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer","volume":"29","author":"Neugut","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/COC.0b013e3182436ec1","article-title":"Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women","volume":"36","author":"Weaver","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-012-2066-9","article-title":"Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)","volume":"134","author":"Neugut","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2016.03.001_bb0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0155","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1532-5415.1985.tb07154.x","article-title":"The psychosocial impact of cancer on the elderly: a comparison with younger patients","volume":"33","author":"Ganz","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jgo.2016.03.001_bb0160","first-page":"372","article-title":"Breast cancer in older women: quality-of-life considerations","volume":"1","author":"Ganz","year":"1994","journal-title":"Cancer Control"},{"key":"10.1016\/j.jgo.2016.03.001_bb0165","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1768::AID-CNCR19>3.0.CO;2-O","article-title":"Age-related differences in the quality of life of breast carcinoma patients after treatment","volume":"86","author":"Wenzel","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2016.03.001_bb0170","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.03.001_bb0175","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0149-2918(98)80139-2","article-title":"Predictors of medication adherence in the elderly","volume":"20","author":"Balkrishnan","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgo.2016.03.001_bb0180","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.1997.03550200063033","article-title":"Evidence-based disease management","volume":"278","author":"Ellrodt","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jgo.2016.03.001_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/jech-2014-204506","article-title":"Social disparities in disease management programmes for coronary heart disease in Germany: a cross-classified multilevel analysis","author":"Bozorgmehr","year":"2015","journal-title":"J Epidemiol Community Health"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406816300194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406816300194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T08:57:21Z","timestamp":1536829041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406816300194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1879406816300194"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2016.03.001","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2016.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}